Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

0.7082 +0.0664 (+10.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,413
Open 0.6554
Bid (Size) 0.6749 (23)
Ask (Size) 0.7082 (3)
Prev. Close 0.6418
Today's Range 0.6445 - 0.7082
52wk Range 0.6101 - 6.800
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
-43.3%
-43.3%
1 Month
+7.1%
+7.1%
3 Month
-33.2%
-33.2%
6 Month
-63.5%
-63.5%
1 Year
-85.7%
-85.7%

More News

Read More
Traders are paying attention to the gapping stocks in Friday's session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wondering what's happening in today's after-hours session?
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Via Chartmill
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
Via Talk Markets

Frequently Asked Questions

Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
What is the current price of Prelude Therapeutics Incorporated - Common Stock?
The current price of Prelude Therapeutics Incorporated - Common Stock is 0.7082
When was Prelude Therapeutics Incorporated - Common Stock last traded?
The last trade of Prelude Therapeutics Incorporated - Common Stock was at 04/11/25 04:00 PM ET
What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 38.82M
How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
Prelude Therapeutics Incorporated - Common Stock has 39M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS